Clincosm LogoSign in Get a demo

Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease

Sponsor
Incyte Corporation (Industry)
Overall Status
Available
CT.gov ID
NCT05544032
Collaborator
(none)

Study Details

Study Description

Brief Summary

Expanded access of Axatilimab to treat a single patient with Chronic Graft versus Host Disease (cGVHD).

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Expanded Access
Official Title:
Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:
    Exclusion Criteria:

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Incyte Corporation

    Investigators

    • Principal Investigator: Betty Hamilton, MD, The Cleveland Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Incyte Corporation
    ClinicalTrials.gov Identifier:
    NCT05544032
    Other Study ID Numbers:
    • I-34176-22-03
    First Posted:
    Sep 16, 2022
    Last Update Posted:
    Sep 16, 2022
    Last Verified:
    Sep 1, 2022
    Keywords provided by Incyte Corporation
    Chronic Graft Vs. Host Disease
    cGVHD
    Additional relevant MeSH terms:
    Graft vs Host Disease

    Study Results

    No Results Posted as of Sep 16, 2022